Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MHB088C in Advanced Solid Tumors
NCT07102004Phase 2Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2023
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MHB088C in solid tumor (advanced stage), small cell lung cancer (SCLC), sponsored by Qilu Pharmaceutical. Started Jun 2023; status: recruiting.
02
Drugs
MHB088C
03
Conditions
solid tumor (advanced stage)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07102004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07102004.